Listen in the Podli app 🎧
Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Featuring an interview with Dr Alexander E Drilon, including the following topics:
- Overview of targetable biomarkers in lung cancer (0:00)
- Biomarker testing for genomic alterations in lung cancer (5:24)
- Overview of ROS1 alterations in lung cancer (13:44)
- Efficacy data with ROS1 inhibitors for lung cancer (17:02)
- Safety data with ROS1 inhibitors for lung cancer (21:15)
- Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56)
- Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16)
- Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)
NCPD information and select publications
